DNDi aims to deliver:
- A new safe, effective and affordable treatment for patients with eumycetoma.
DNDi’s current mycetoma portfolio includes:
One project in the development phase:
- Fosravuconazole: The anti-fungal drug fosravuconazole (also known as E1224), an orally bioavailable azole that is under development for Chagas disease, may be an effective and affordable treatment for eumycetoma. A prodrug, fosravuconazole is rapidly converted to ravuconazole, which has been shown to have potent in vitro activity against one of the causative agents of eumycetoma, Madurella mycetomatis. Its pharmacokinetic properties are favourable and its toxicity is low.
A Phase II/III randomized controlled trial will be conducted with the WHO Collaborating Centre on Mycetoma in Khartoum to study the efficacy of fosravuconazole in moderate lesions in comparison with the current treatment, itraconazole. The primary objective of this double-blind, randomized, single-centre study will be to demonstrate superiority of fosravuconazole over itraconazole after 12 months’ treatment. Protocols were finalized in 2016 and recruitment of patients (with a target of 136 participants) should start early 2017. An interim analysis will be conducted at three months.